A new genome-wide study uncovers evidence of the first three-way relationships between human genetic variation, variation in the fungal component of the human microbiome — known as the mycobiome — and risk of developing chronic […]
Resbiotic Nutrition, Inc., a physician-scientist founded health and wellness company, today announced it has raised a total of $14.5 million, including a recently concluded $8 million Series A round supported by major shareholders Sororibus Capital and Biostack […]
A key group of beneficial gut microbes has been found to co-evolve alongside their animal hosts, opening the door to new targeted probiotic and dietary interventions for both animals and humans. In a study published […]
When scientists discovered how bacteria protect themselves against viral invaders, called phages, in the early 2000s, little did they know they’d stumbled upon a revolutionary tool researchers could use to edit the DNA of living […]
Persephone Biosciences, a pioneering biotech company focused on unlocking the potential of the microbiome to impact human health, today announced the launch of its first consumer product: a daily synergistic synbiotic for infants and toddlers. […]
Following the closure of Bacthera’s CDMO activities, Lallemand has acquired a broad range of state-of-the-art equipment to produce drug substances and drug products in anaerobic conditions, reinforcing its GMP Pharma production capabilities for next-generation strains. […]
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced the successful closing of a €55 million (US$64 million) Series B financing round. The round was led by […]
Corn is one of the most valuable cash crops globally, with annual grain production in the United States alone valued at nearly $80 billion. Fungicides are widely used to protect crops and promote yield, but […]
In the past 10 years, there has been significant interest in new classes of active pharmaceutical ingredients (APIs). These novel APIs include live biotherapeutics, which are used for microbiome targeting drugs, oral biologics like GLP1 […]
COPENHAGEN, Denmark, Aug. 07, 2025 (GLOBE NEWSWIRE) — SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from […]
Postbiotics are a quickly-growing category of products targeting gut health and other applications, such as skin. Defined in 2021 as “a preparation of inanimate microorganisms and/or their components that confers a health benefit on the […]